Search

Your search keyword '"Gelmon, Karen A."' showing total 1,096 results
Start Over Author "Gelmon, Karen A."

Refine your results

more »

more »

more »

more »

more »
1,096 results on '"Gelmon, Karen A."'

157. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

Author

Shah, Sohrab P., Morin, Ryan D., Khattra, Jaswinder, Prentice, Leah, Pugh, Trevor, Burleigh, Angela, Delaney, Allen, Gelmon, Karen, Guliany, Ryan, Senz, Janine, Steidl, Christian, Holt, Robert A., Jones, Steven, Sun, Mark, Leung, Gillian, Moore, Richard, Severson, Tesa, Taylor, Greg A., Teschendorff, Andrew E., Tse, Kane, Turashvili, Gulisa, Varhol, Richard, Warren, Rene L., Watson, Peter, Zhao, Yongjun, Caldas, Carlos, Huntsman, David, Hirst, Martin, Marra, Marco A., and Aparicio, Samuel

Subjects
Gene mutations -- Health aspects -- Genetic aspects, Breast tumors -- Genetic aspects -- Development and progression, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Recent advances in next generation sequencing (1-4} have made it possible to precisely characterize all somatic coding mutations that occur during the development and progression of individual cancers. Here we used these approaches to sequence the genomes (>43-fold coverage) and transcriptomes of an oestrogen-receptor-α-positive metastatic lobular breast cancer at depth. We found 32 somatic non-synonymous coding mutations present in the metastasis, and measured the frequency of these somatic mutations in DNA from the primary tumour of the same patient, which arose 9 years earlier. Five of the 32 mutations (in ABCB11, HAUS3, SLC24A4, SNX4 and PALB2) were prevalent in the DNA of the primary tumour removed at diagnosis 9years earlier, six (in KIFI C, USP28, MYH8, MORCI, KMA1468 and RNASEH2A) were present at lower frequencies (1-13%), 19 were not detected in the primary tumour, and two were undetermined. The combined analysis of genome and transcriptome data revealed two new RNA-editing events that recode the amino acid sequence of SRP9 and COG3. Taken together, our data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression., Lobular breast cancer is an oestrogen-receptor-positive ([ER.sup.+], also known as [ESRl.sup.+]) subtype of breast cancer (approximately 15% of all breast cancers). It is usually of low-intermediate histological grade and can [...]

Published
2009

160. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up

Author

Finn, Richard S., primary, Rugo, Hope S., additional, Gelmon, Karen A., additional, Cristofanilli, Massimo, additional, Colleoni, Marco, additional, Loi, Sherene, additional, Schnell, Patrick, additional, Lu, Dongrui R., additional, Theall, Kathy Puyana, additional, Mori, Ave, additional, Gauthier, Eric, additional, Bananis, Eustratios, additional, Turner, Nicholas C., additional, and Diéras, Véronique, additional

Published
2021
Full Text
View/download PDF

163. Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

Author

Loibl, Sibylle, primary, Marmé, Frederik, additional, Martin, Miguel, additional, Untch, Michael, additional, Bonnefoi, Hervé, additional, Kim, Sung-Bae, additional, Bear, Harry, additional, Carthy, Nicole Mc, additional, Olivé, Mireia Melé, additional, Gelmon, Karen, additional, Sáenz, José García, additional, Kelly, Catherine M, additional, Reimer, Toralf, additional, Toi, Masakazu, additional, Rugo, Hope S, additional, Seiler, Sabine, additional, Nekljudova, Valentina, additional, Denkert, Carsten, additional, Gnant, Michael, additional, Makris, Andreas, additional, Burchardi, Nicole, additional, and von Minckwitz, Gunter, additional

Published
2021
Full Text
View/download PDF

164. Abstract PS10-14: Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2

Author

Gelmon, Karen, primary, Walshe, Janice M, additional, Mahtani, Reshma, additional, Joy, Anil A, additional, Karuturi, Meghan, additional, Neven, Patrick, additional, Lu, Dongrui Ray, additional, Kim, Sindy, additional, Schnell, Patrick, additional, Bananis, Eustratios, additional, and Schwartzberg, Lee, additional

Published
2021
Full Text
View/download PDF

165. Abstract PD13-04: Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases

Author

Wardley, Andrew, primary, Mueller, Volkmar, additional, Paplomata, Elisavet, additional, Crouzet, Laurence, additional, Iqbal, Nayyer, additional, Aithal, Sramila, additional, Block, Margaret, additional, Cold, Søren, additional, By, Marie-Agnes, additional, Hahn, Olwen, additional, Poosarla, Teja, additional, Stringer-Reasor, Erica, additional, Colleoni, Marco, additional, Cameron, David, additional, Curigliano, Giuseppe, additional, DeBusk, Kendra, additional, Siadak, Muriel, additional, Ramos, Jorge, additional, An, Xuebei, additional, and Gelmon, Karen, additional

Published
2021
Full Text
View/download PDF

169. The effect of metformin vs placebo on sex hormones in CCTG MA.32

Author

Pimentel, Isabel, Chen, Bingshu E, Lohmann, Ana Elisa, Ennis, Marguerite, Ligibel, Jennifer, Shepherd, Lois, Hershman, Dawn L, Whelan, Timothy, Stambolic, Vuk, Mayer, Ingrid, Hobday, Timothy, Lemieux, Julie, Thompson, Alastair, Rastogi, Priya, Gelmon, Karen, Rea, Daniel, Rabaglio, Manuela, Ellard, Susan, Mates, Mihaela, Bedard, Philippe, Pitre, Lacey, Vandenberg, Theodore, Jo Dowling, Ryan, Parulekar, Wendy, and Goodwin, Pamela J

Subjects
nutritional and metabolic diseases, 610 Medicine & health
Abstract

BACKGROUND Metformin has been associated with lower breast cancer risk and improved outcomes in observational studies. Multiple biologic mechanisms have been proposed, including a recent report of altered sex hormones (SHs). We evaluated the effect of metformin on SHs in MA.32, a phase III trial of nondiabetic BC subjects randomized to metformin or placebo. METHODS We studied the subgroup of post-menopausal hormone receptor negative BC subjects not receiving endocrine treatment who provided fasting blood at baseline and at 6 months after randomization. Sex hormone binding globulin (SHBG), bioavailable testosterone (BT) and estradiol levels were assayed using ECLIA (electrochemiluminescense immunoassay). Change from baseline to 6 months between study arms was compared using Wilcoxon sum rank tests and regression models. RESULTS 312 women were eligible (141 metformin vs 171 placebo); the majority of subjects in each arm had T1/2, N0, HER2 negative BC and had received (neo)adjuvant chemotherapy. Mean age ± SD was 58.1±6.9 vs 57.5±7.9 years, mean BMI was 27.3±5.2 vs 28.9±6.4 kg/m2 for metformin vs placebo respectively. Median estradiol decreased between baseline and 6 months on metformin vs placebo (-5.7 vs 0 pmol/L; p

Published
2020

170. Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)

Author

Murthy, Rashmi, Loi, Sherene, Okines, Alicia, Paplomata, Elisavet, Hamilton, Erika, Hurvitz, Sara, Lin, Nancy, Borges, Virginia, Abramson, Vandana Gupta, Anders, Carey, Bedard, Philippe L., Oliveira, Mafalda, Jakobsen, Erik, Bachelot, Thomas, Shachar, Shlomit S., Mueller, Volkmar, Braga, Sofia, Duhoux, Francois P., Greil, Richard, Cameron, David, Carey, Lisa, Curigliano, Giuseppe, Gelmon, Karen, Hortobagyi, Gabriel, Krop, Ian, Loibl, Sibylle, Pegram, Mark, Slamon, Dennis, Palanca-Wessels, Maria Corinna, Walker, Luke, Feng, Wentao, and Winer, Eric

Published
2020

171. PUB0201081895

Author

Kirkham, Amy A., Virani, Sean A., Bland, Kelcey A., McKenzie, Donald C., Gelmon, Karen A., Warburton, Darren E. R., and Campbell, Kristin L.

Subjects
anthracyclines, exercise, cardiotoxicity, hemodynamics, heart function tests
Abstract

Introduction Preclinical data demonstrate the potential for exercise training to protect against anthracycline-related cardiotoxicity, but this remains to be shown in humans. Purpose To assess whether exercise training during anthracycline-based chemotherapy for treatment of breast cancer affects resting cardiac function and hemodynamics. Methods In this prospective, non-randomized controlled study, 26 women who participated in aerobic and resistance training 3×/wk during chemotherapy were compared to 11 women receiving usual care. Two-dimensional echocardiography was performed before and 7–14 days after completion of anthracycline-based chemotherapy. Pre- and post-anthracycline cardiac function and hemodynamic variables were compared within each group with paired t-tests; the change was compared between groups using ANCOVA with adjustment for baseline values. Results Left ventricular longitudinal strain, volumes, ejection fraction, E/A ratio, and mass did not change in either group. Hemoglobin, hematocrit, and mean arterial pressure decreased significantly from baseline in both groups (all p

Published
2020

172. Triple negative breast cancer – Understanding the clinical implications of heterogeneity

Author

Gelmon Karen and LeVasseur N

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Breast tumours, Medicine, business, Pathogenicity, Human Epidermal Growth Factor Receptor 2, Triple negative, Germline, Triple-negative breast cancer
Abstract

Triple negative breast cancers (TNBC) have long been associated with a worse prognosis in contrast to hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) positive breast tumours. However, advances in the classification and molecular categorization of TNBC have led to meaningful advances, highlighting substantial TNBC heterogeneity and distinct histomolecular subtypes. While TNBC has historically been treated with single or combined chemotherapeutic agents, novel targeted therapies are being developed and evaluated. A better understanding of oncogenic drivers and the pathogenicity of germline and somatic mutations has also paved the way to new targeted treatments. More recently, the neoadjuvant space has become increasingly popular to better understand the behaviour of TNBC subtypes, leading to the development of biomarker-driven trials to better select targeted treatments. This has ultimately led to a number of advances and new potential targets for treatment which remain under investigation and will undoubtedly lead to a better understanding and personalized approach for patients diagnosed with TNBC.

Published
2020

173. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Author

Smith, Ian, Procter, Marion, Gelber, Richard D., Guillaume, Sebastien, Feyereislova, Andrea, Dowsett, Mitch, Goldhirsch, Aron, Untch, Michael, Mariani, Gabriella, Baselga, Jose, Kaufmann, Manfred, Cameron, David, Bell, Richard, Bergh, Jonas, Coleman, Robert, Wardley, Andrew, Harbeck, Nadia, Lopez, Roberto I., Mallmann, Peter, Gelmon, Karen, Wilcken, Nicholas, Wist, Erik, Rovira, Pedro Sanchez, and Piccart-Gebhart, Martine J.

Subjects
Herceptin (Medication) -- Research, Herceptin (Medication) -- Health aspects, Breast cancer -- Drug therapy
Published
2007

184. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Author

Curtis, Christina, Shah, Sohrab P., Chin, Suet-Feung, Turashvili, Gulisa, Rueda, Oscar M., Dunning, Mark J., Speed, Doug, Lynch, Andy G., Samarajiwa, Shamith, Yuan, Yinyin, Gräf, Stefan, Ha, Gavin, Haffari, Gholamreza, Bashashati, Ali, Russell, Roslin, McKinney, Steven, Aparicio, Samuel, Brenton, James D., Ellis, Ian, Huntsman, David, Pinder, Sarah, Purushotham, Arnie, Murphy, Leigh, Caldas, Carlos, Bardwell, Helen, Ding, Zhihao, Jones, Linda, Liu, Bin, Papatheodorou, Irene, Sammut, Stephen J., Wishart, Gordon, Chia, Steven, Gelmon, Karen, Speers, Caroline, Watson, Peter, Blamey, Roger, Green, Andrew, Macmillan, Douglas, Rakha, Emad, Gillett, Cheryl, Grigoriadis, Anita, de Rinaldis, Emanuele, Tutt, Andy, Parisien, Michelle, Troup, Sandra, Chan, Derek, Fielding, Claire, Maia, Ana-Teresa, McGuire, Sarah, Osborne, Michelle, Sayalero, Sara M., Spiteri, Inmaculada, Hadfield, James, Bell, Lynda, Chow, Katie, Gale, Nadia, Kovalik, Maria, Ng, Ying, Prentice, Leah, Tavaré, Simon, Markowetz, Florian, Langerød, Anita, Provenzano, Elena, and Børresen-Dale, Anne-Lise

Published
2012
Full Text
View/download PDF

185. Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Author

Goss, Paul E., Ingle, James N., Alés-Martínez, José E., Cheung, Angela M., Chlebowski, Rowan T., Wactawski-Wende, Jean, McTiernan, Anne, Robbins, John, Johnson, Karen C., Martin, Lisa W., Winquist, Eric, Sarto, Gloria E., Garber, Judy E., Fabian, Carol J., Pujol, Pascal, Maunsell, Elizabeth, Farmer, Patricia, Gelmon, Karen A., Tu, Dongsheng, and Richardson, Harriet

Published
2011
Full Text
View/download PDF

186. Higher serum PD‐L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial

Author

Moku, Prashanth, primary, Shepherd, Lois, additional, Ali, Suhail M., additional, Leitzel, Kim, additional, Parulekar, Wendy R., additional, Zhu, Liting, additional, Virk, Shakeel, additional, Nomikos, Dora, additional, Aparicio, Samuel, additional, Gelmon, Karen, additional, Drabick, Joe, additional, Cream, Leah, additional, Halstead, E. Scott, additional, Umstead, Todd M., additional, Mckeone, Dan, additional, Polimera, Hyma, additional, Maddukuri, Ashok, additional, Ali, Aamnah, additional, Nagabhairu, Vinod, additional, Poulose, Joyson, additional, Pancholy, Neha, additional, Spiegel, Howard, additional, Chen, Bingshu E., additional, and Lipton, Allan, additional

Published
2020
Full Text
View/download PDF

187. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer

Author

Cortés, Javier, primary, Diéras, Véronique, additional, Lorenzen, Sylvie, additional, Montemurro, Filippo, additional, Riera-Knorrenschild, Jorge, additional, Thuss-Patience, Peter, additional, Allegrini, Giacomo, additional, De Laurentiis, Michelino, additional, Lohrisch, Caroline, additional, Oravcová, Eva, additional, Perez-Garcia, Jose M., additional, Ricci, Francesco, additional, Sakaeva, Dina, additional, Serpanchy, Rosanne, additional, Šufliarský, Jozef, additional, Vidal, Maria, additional, Irahara, Natsumi, additional, Wohlfarth, Christine, additional, Aout, Mounir, additional, and Gelmon, Karen, additional

Published
2020
Full Text
View/download PDF

188. The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32

Author

Pimentel, Isabel, primary, Chen, Bingshu E, additional, Lohmann, Ana Elisa, additional, Ennis, Marguerite, additional, Ligibel, Jennifer, additional, Shepherd, Lois, additional, Hershman, Dawn L, additional, Whelan, Timothy, additional, Stambolic, Vuk, additional, Mayer, Ingrid, additional, Hobday, Timothy, additional, Lemieux, Julie, additional, Thompson, Alastair, additional, Rastogi, Priya, additional, Gelmon, Karen, additional, Rea, Daniel, additional, Rabaglio, Manuela, additional, Ellard, Susan, additional, Mates, Mihaela, additional, Bedard, Philippe, additional, Pitre, Lacey, additional, Vandenberg, Theodore, additional, Dowling, Ryan J O, additional, Parulekar, Wendy, additional, and Goodwin, Pamela J, additional

Published
2020
Full Text
View/download PDF

189. Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology

Author

Dixon, Katherine, primary, Young, Sean, additional, Shen, Yaoqing, additional, Thibodeau, My Linh, additional, Fok, Alexandra, additional, Pleasance, Erin, additional, Zhao, Eric, additional, Jones, Martin, additional, Aubert, Geraldine, additional, Armstrong, Linlea, additional, Virani, Alice, additional, Regier, Dean, additional, Gelmon, Karen, additional, Renouf, Dan, additional, Chia, Stephen, additional, Bosdet, Ian, additional, Rassekh, S Rod, additional, Deyell, Rebecca J, additional, Yip, Stephen, additional, Fisic, Ana, additional, Titmuss, Emma, additional, Abadi, Shirin, additional, Jones, Steven J M, additional, Sun, Sophie, additional, Karsan, Aly, additional, Marra, Marco, additional, Laskin, Janessa, additional, Lim, Howard, additional, and Schrader, Kasmintan A, additional

Published
2020
Full Text
View/download PDF

190. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Author

Hafez, Navid, primary, Soliman, Hatem Hussein, additional, Fu, Siqing, additional, Gelmon, Karen A., additional, Abdul Razak, Albiruni Ryan, additional, Munster, Pamela N., additional, Vaishampayan, Ulka N., additional, Kato, Shumei, additional, Lara, Primo, additional, Swisher, Elizabeth M., additional, Nixon, Andrew B., additional, Patel, Abhijit, additional, Shyr, Yu, additional, Ivy, S. Percy, additional, LoRusso, Patricia, additional, and Kim, Joseph W., additional

Published
2020
Full Text
View/download PDF

191. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).

Author

Okines, Alicia Frances Clare, primary, Paplomata, Elisavet, additional, Wahl, Tanya A., additional, Wright, Gail Lynn Shaw, additional, Sutherland, Stephanie, additional, Jakobsen, Erik, additional, Valdes, Frances, additional, Chan, Arlene, additional, Clark, Amy Sanders, additional, Conlin, Alison Katherine, additional, Lustberg, Maryam B., additional, Specht, Jennifer M., additional, Pluard, Timothy J., additional, Zhu, Xiaofu, additional, Krop, Ian E., additional, Gelmon, Karen A., additional, Slamon, Dennis J., additional, Ramos, Jorge, additional, An, Grace, additional, and Hamilton, Erika Paige, additional

Published
2020
Full Text
View/download PDF

193. Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.

Author

Gelmon, Karen A., primary, Fasching, Peter A., additional, Couch, Fergus, additional, Balmana Gelpi, Judith, additional, Delaloge, Suzette, additional, Labidi-Galy, Intidhar, additional, Bennett, James, additional, McCutcheon, Susan, additional, Ano, Sabine, additional, and O'Shaughnessy, Joyce, additional

Published
2020
Full Text
View/download PDF

194. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes

Author

Pleasance, Erin, primary, Titmuss, Emma, additional, Williamson, Laura, additional, Kwan, Harwood, additional, Culibrk, Luka, additional, Zhao, Eric Y., additional, Dixon, Katherine, additional, Fan, Kevin, additional, Bowlby, Reanne, additional, Jones, Martin R., additional, Shen, Yaoqing, additional, Grewal, Jasleen K., additional, Ashkani, Jahanshah, additional, Wee, Kathleen, additional, Grisdale, Cameron J., additional, Thibodeau, My Linh, additional, Bozoky, Zoltan, additional, Pearson, Hillary, additional, Majounie, Elisa, additional, Vira, Tariq, additional, Shenwai, Reva, additional, Mungall, Karen L., additional, Chuah, Eric, additional, Davies, Anna, additional, Warren, Mya, additional, Reisle, Caralyn, additional, Bonakdar, Melika, additional, Taylor, Gregory A., additional, Csizmok, Veronika, additional, Chan, Simon K., additional, Zong, Zusheng, additional, Bilobram, Steve, additional, Muhammadzadeh, Amir, additional, D’Souza, Darryl, additional, Corbett, Richard D., additional, MacMillan, Daniel, additional, Carreira, Marcus, additional, Choo, Caleb, additional, Bleile, Dustin, additional, Sadeghi, Sara, additional, Zhang, Wei, additional, Wong, Tina, additional, Cheng, Dean, additional, Brown, Scott D., additional, Holt, Robert A., additional, Moore, Richard A., additional, Mungall, Andrew J., additional, Zhao, Yongjun, additional, Nelson, Jessica, additional, Fok, Alexandra, additional, Ma, Yussanne, additional, Lee, Michael K. C., additional, Lavoie, Jean-Michel, additional, Mendis, Shehara, additional, Karasinska, Joanna M., additional, Deol, Balvir, additional, Fisic, Ana, additional, Schaeffer, David F., additional, Yip, Stephen, additional, Schrader, Kasmintan, additional, Regier, Dean A., additional, Weymann, Deirdre, additional, Chia, Stephen, additional, Gelmon, Karen, additional, Tinker, Anna, additional, Sun, Sophie, additional, Lim, Howard, additional, Renouf, Daniel J., additional, Laskin, Janessa, additional, Jones, Steven J. M., additional, and Marra, Marco A., additional

Published
2020
Full Text
View/download PDF

195. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

Author

Gelmon, Karen A., primary, Cristofanilli, Massimo, additional, Rugo, Hope S., additional, DeMichele, Angela M., additional, Joy, Anil A., additional, Castrellon, Aurelio, additional, Sleckman, Bethany, additional, Mori, Ave, additional, Theall, Kathy Puyana, additional, Lu, Dongrui R., additional, Huang, Xin, additional, Bananis, Eustratios, additional, Finn, Richard S., additional, and Slamon, Dennis J., additional

Published
2020
Full Text
View/download PDF

196. Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies

Author

Hilton, John, primary, Gelmon, Karen, additional, Cescon, David, additional, Tinker, Anna, additional, Jonker, Derek, additional, Goodwin, Rachel, additional, Laurie, Scott, additional, Hansen, Aaron, additional, Aparicio, Samuel, additional, Soong, John, additional, Hagerman, Linda, additional, Lui, Hongbo, additional, Bedard, Philippe, additional, Pritchard, Kathleen, additional, Tu, Dongsheng, additional, and Seymour, Lesley, additional

Published
2020
Full Text
View/download PDF

197. Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)

Author

Murthy, Rashmi, primary, Loi, Sherene, additional, Okines, Alicia, additional, Paplomata, Elisavet, additional, Hamilton, Erika, additional, Hurvitz, Sara, additional, Lin, Nancy, additional, Borges, Virginia, additional, Abramson, Vandana Gupta, additional, Anders, Carey, additional, Bedard, Philippe L, additional, Oliveira, Mafalda, additional, Jakobsen, Erik, additional, Bachelot, Thomas, additional, Shachar, Shlomit S, additional, Mueller, Volkmar, additional, Braga, Sofia, additional, Duhoux, Francois P, additional, Greil, Richard, additional, Cameron, David, additional, Carey, Lisa, additional, Curigliano, Giuseppe, additional, Gelmon, Karen, additional, Hortobagyi, Gabriel, additional, Krop, Ian, additional, Loibl, Sibylle, additional, Pegram, Mark, additional, Slamon, Dennis, additional, Palanca-Wessels, Maria Corinna, additional, Walker, Luke, additional, Feng, Wentao, additional, and Winer, Eric, additional

Published
2020
Full Text
View/download PDF

198. Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis

Author

Finn, Richard S, primary, Rugo, Hope S, additional, Gelmon, Karen, additional, Cristofanilli, Massimo, additional, Colleoni, Marco, additional, Loi, Sherene, additional, Schnell, Patrick, additional, Lu, Dongrui R, additional, Theall, Kathy P, additional, Mori, Ave, additional, Gauthier, Eric, additional, Bananis, Eustratios, additional, Turner, Nicholas C, additional, and Diéras, Véronique, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results